Suppr超能文献

与黄热病疫苗相关的严重不良事件。

Serious adverse events associated with yellow fever vaccine.

作者信息

de Menezes Martins Reinaldo, Fernandes Leal Maria da Luz, Homma Akira

机构信息

a Bio-Manguinhos/Fiocruz ; Rio de Janeiro , Brazil.

出版信息

Hum Vaccin Immunother. 2015;11(9):2183-7. doi: 10.1080/21645515.2015.1022700.

Abstract

Yellow fever vaccine was considered one of the safest vaccines, but in recent years it was found that it could rarely cause invasive and disseminated disease in some otherwise healthy individuals, with high lethality. After extensive studies, although some risk factors have been identified, the real cause of causes of this serious adverse event are largely unknown, but findings point to individual host factors. Meningoencephalitis, once considered to happen only in children less than 6 months of age, has also been identified in older children and adults, but with good prognosis. Efforts are being made to develop a safer yellow fever vaccine, and an inactivated vaccine or a vaccine prepared with the vaccine virus envelope produced in plants are being tested. Even with serious and rare adverse events, yellow fever vaccine is the best way to avoid yellow fever, a disease of high lethality and should be used routinely in endemic areas, and on people from non-endemic areas that could be exposed, according to a careful risk-benefit analysis.

摘要

黄热病疫苗曾被认为是最安全的疫苗之一,但近年来发现,在一些原本健康的个体中,它极少会引发侵袭性和播散性疾病,且致死率很高。经过广泛研究,虽然已确定了一些风险因素,但这种严重不良事件的真正成因在很大程度上仍不明确,但研究结果指向个体宿主因素。脑膜炎曾被认为仅发生在6个月以下的儿童中,如今在年龄较大的儿童和成人中也有发现,但预后良好。目前正在努力研发更安全的黄热病疫苗,一种灭活疫苗或用植物生产的疫苗病毒包膜制备的疫苗正在进行测试。即便存在严重且罕见的不良事件,黄热病疫苗仍是预防黄热病的最佳方式,黄热病是一种致死率很高的疾病,根据仔细的风险效益分析,在流行地区以及可能暴露的非流行地区人群中应常规使用。

相似文献

1
Serious adverse events associated with yellow fever vaccine.
Hum Vaccin Immunother. 2015;11(9):2183-7. doi: 10.1080/21645515.2015.1022700.
2
Adverse events following yellow fever immunization: Report and analysis of 67 neurological cases in Brazil.
Vaccine. 2014 Nov 20;32(49):6676-82. doi: 10.1016/j.vaccine.2014.05.003. Epub 2014 May 14.
3
Yellow Fever outbreaks in unvaccinated populations, Brazil, 2008-2009.
PLoS Negl Trop Dis. 2014 Mar 13;8(3):e2740. doi: 10.1371/journal.pntd.0002740. eCollection 2014 Mar.
4
Safety profile of the yellow fever vaccine Stamaril®: a 17-year review.
Expert Rev Vaccines. 2013 Nov;12(11):1351-68. doi: 10.1586/14760584.2013.836320. Epub 2013 Sep 25.
5
Active and passive surveillance of yellow fever vaccine 17D or 17DD-associated serious adverse events: systematic review.
Vaccine. 2011 Jun 20;29(28):4544-55. doi: 10.1016/j.vaccine.2011.04.055. Epub 2011 May 5.
7
Adverse events following yellow fever preventive vaccination campaigns in eight African countries from 2007 to 2010.
Vaccine. 2013 Apr 3;31(14):1819-29. doi: 10.1016/j.vaccine.2013.01.054. Epub 2013 Feb 7.
8
An inactivated cell-culture vaccine against yellow fever.
N Engl J Med. 2011 Apr 7;364(14):1326-33. doi: 10.1056/NEJMoa1009303.
9
Viscerotropic disease and acute uveitis following yellow fever vaccination: a case report.
BMC Infect Dis. 2020 Feb 10;20(1):116. doi: 10.1186/s12879-020-4838-x.

引用本文的文献

1
Insect-Specific Flaviviruses Have Potential Applications as a Scaffold for Pathogenic Flavivirus Vaccines.
Vaccines (Basel). 2025 Jul 21;13(7):769. doi: 10.3390/vaccines13070769.
3
Cynomolgus macaques as a translational model of human immune responses to yellow fever 17D vaccination.
J Virol. 2024 May 14;98(5):e0151623. doi: 10.1128/jvi.01516-23. Epub 2024 Apr 3.
4
Rapid Generation of Recombinant Flaviviruses Using Circular Polymerase Extension Reaction.
Vaccines (Basel). 2023 Jul 17;11(7):1250. doi: 10.3390/vaccines11071250.
5
The role of vaccines in the COVID-19 pandemic: what have we learned?
Semin Immunopathol. 2024 Jan;45(4-6):451-468. doi: 10.1007/s00281-023-00996-2. Epub 2023 Jul 12.
6
Therapeutic neutralizing monoclonal antibody administration protects against lethal yellow fever virus infection.
Sci Transl Med. 2023 Mar 29;15(689):eade5795. doi: 10.1126/scitranslmed.ade5795.
7
Yellow Fever Vaccine-Related Neurotropic Disease in Brazil Following Immunization with 17DD.
Vaccines (Basel). 2023 Feb 15;11(2):445. doi: 10.3390/vaccines11020445.
8
Hemorrhagic fever viruses: Pathogenesis, therapeutics, and emerging and re-emerging potential.
Front Microbiol. 2022 Oct 25;13:1040093. doi: 10.3389/fmicb.2022.1040093. eCollection 2022.
9
A Systematic Review and a Meta-Analysis of the Yellow Fever Vaccine in the Elderly Population.
Vaccines (Basel). 2022 Apr 30;10(5):711. doi: 10.3390/vaccines10050711.

本文引用的文献

1
Yellow fever.
J Clin Virol. 2015 Mar;64:160-73. doi: 10.1016/j.jcv.2014.08.030. Epub 2014 Oct 24.
2
Alterations of the immune system in thymic malignancies.
J Thorac Oncol. 2014 Sep;9(9 Suppl 2):S137-42. doi: 10.1097/JTO.0000000000000299.
3
Risk groups for yellow fever vaccine-associated viscerotropic disease (YEL-AVD).
Vaccine. 2014 Oct 7;32(44):5769-75. doi: 10.1016/j.vaccine.2014.08.051. Epub 2014 Sep 3.
4
Human genetic variation and yellow fever mortality during 19th century U.S. epidemics.
mBio. 2014 Jun 3;5(3):e01253-14. doi: 10.1128/mBio.01253-14.
5
Adverse events following yellow fever immunization: Report and analysis of 67 neurological cases in Brazil.
Vaccine. 2014 Nov 20;32(49):6676-82. doi: 10.1016/j.vaccine.2014.05.003. Epub 2014 May 14.
6
Yellow fever vaccine-associated adverse events following extensive immunization in Argentina.
Vaccine. 2014 Mar 5;32(11):1266-72. doi: 10.1016/j.vaccine.2014.01.015. Epub 2014 Jan 21.
7
Risk of yellow fever vaccine-associated viscerotropic disease among the elderly: a systematic review.
Vaccine. 2013 Dec 2;31(49):5798-805. doi: 10.1016/j.vaccine.2013.09.030. Epub 2013 Sep 27.
8
Adverse events following yellow fever preventive vaccination campaigns in eight African countries from 2007 to 2010.
Vaccine. 2013 Apr 3;31(14):1819-29. doi: 10.1016/j.vaccine.2013.01.054. Epub 2013 Feb 7.
9
17DD yellow fever vaccine: a double blind, randomized clinical trial of immunogenicity and safety on a dose-response study.
Hum Vaccin Immunother. 2013 Apr;9(4):879-88. doi: 10.4161/hv.22982. Epub 2013 Jan 30.
10
Immunogenicity and safety of yellow fever vaccine among 115 HIV-infected patients after a preventive immunisation campaign in Mali.
Trans R Soc Trop Med Hyg. 2012 Jul;106(7):437-44. doi: 10.1016/j.trstmh.2012.04.002. Epub 2012 May 22.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验